Sotevtamab + FOLFOX for Colorectal Cancer

(EGIA-003 Trial)

Recruiting at 1 trial location

Overseen By Julie Laurin, B. Pharm, Ph.D.

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Alethia Biotherapeutics

Must not be taking: Anti-VGFR, Anti-EGFR, Anti-VEGF, Immunosuppressants

Disqualifiers: MMR-deficient tumor, Hereditary cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

17 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new treatment combination for colorectal cancer that has spread to the liver. It combines Sotevtamab (an anti-clusterin monoclonal antibody) with FOLFOX, a common chemotherapy regimen, to determine if they are more effective together before surgery to remove the cancer. The trial seeks individuals with colorectal cancer that has primarily spread to the liver and who have not yet received chemotherapy for this spread. Participants will receive medication and undergo surgery to remove liver tumors. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you cannot take certain cancer treatments or high doses of steroids while participating. It's best to discuss your specific medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that Sotevtamab, the experimental treatment in this study, has been tested in patients with advanced solid tumors. Early results suggest it can block certain tumor markers, which is promising. However, detailed safety information from these studies remains limited in the sources provided.

FOLFOX, a well-known chemotherapy treatment, is often used for colorectal cancer and has been widely studied. A large study with over 3,000 patients found that it can cause some side effects, such as a low level of white blood cells (neutropenia) that can lead to infections, but these are generally manageable.

Since this trial is in a mid-stage phase, the treatment has already been tested for basic safety in earlier studies. This suggests that Sotevtamab, when combined with FOLFOX, might be well-tolerated, but more data is needed for a clearer picture. Always consult a doctor to understand what this means for individual circumstances. ^{1 2 3 4 5}

Why are researchers excited about this study treatment for colorectal cancer?

Researchers are excited about Sotevtamab combined with FOLFOX for colorectal cancer because it introduces a novel mechanism of action. Sotevtamab is a monoclonal antibody targeting specific cancer cell markers, potentially enhancing the effectiveness of FOLFOX, a well-established chemotherapy regimen. This combination could offer a more targeted approach, potentially improving outcomes and reducing side effects compared to traditional chemotherapy alone.

What evidence suggests that Sotevtamab + FOLFOX could be an effective treatment for colorectal cancer?

This trial will evaluate the combination of Sotevtamab and FOLFOX for colorectal cancer. Research has shown that Sotevtamab, when combined with FOLFOX, may help treat various cancer types. In lab and animal studies, Sotevtamab blocks a protein called clusterin, which slows cancer growth and spread. This protein usually aids cancer cell survival and movement, so blocking it can prevent tumors from spreading. Early research suggests that this combination could effectively treat colorectal cancer, particularly when it has spread to the liver. FOLFOX is a well-known chemotherapy treatment, and adding Sotevtamab aims to enhance its effectiveness by targeting cancer cells more precisely. ^{6 7 8 9 10}

Are You a Good Fit for This Trial?

This trial is for colorectal cancer patients with liver metastases. Participants must be eligible for surgery to remove these metastases and have not yet had any treatment specifically targeting the liver tumors.

Inclusion Criteria

I can take care of myself but might not be able to do heavy physical work.

Participants must have given written personally signed and dated informed consent to participate in the trial in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines, before completing any trial related procedures.

I have recovered from my last cancer treatment's side effects.

Exclusion Criteria

Participants with a known history of human immunodeficiency (HIV).

I have a genetic form of colorectal cancer.

Participants who are currently participating or have participated in a trial of an investigational agent or using an investigational device within 21 days of the first dose of trial treatment. The 21-day window should be calculated using the last dose of an investigational agent or last use of an investigational device.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Sotevtamab at 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles

12 weeks

Weekly visits for Sotevtamab, bi-weekly visits for FOLFOX

Surgery

Participants undergo liver metastasis resection with or without primary cancer resection following recovery from preoperative neoadjuvant systemic chemotherapy

1-2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including evaluation of treatment-emergent adverse events and pathological response

4-6 weeks

What Are the Treatments Tested in This Trial?

Interventions

• FOLFOX
• Sotevtamab

Trial Overview The study tests Sotevtamab, given weekly, combined with FOLFOX chemotherapy every two weeks. This regimen is followed for six cycles before surgical removal of the liver metastases.

How Is the Trial Designed?

Group I: Sotevtamab and FOLFOX Experimental Treatment 2 Interventions

Sotevtamab at 800 mg IV infusion once weekly on Days 1 and 8 for 6 cycles combined with FOLFOX (oxaliplatin 85 mg/m² IV infusion + leucovorin 400 mg/m² IV infusion + 5-Fluorouracil (5-FU) 400 mg/m² IV bolus + 5-FU 2400 mg/m² continuous IV infusion over 46 hours) once every 2 weeks on Day 1 for the first 4 cycles.

Who Is Running the Clinical Trial?

Alethia Biotherapeutics

Lead Sponsor

Trials

3

Recruited

70+

Published Research Related to This Trial

In patients with inoperable or metastatic colorectal cancer, initial treatment with single-agent fluorouracil (or capecitabine) is recommended over combination therapies when the disease is unlikely to become operable, as it does not shorten overall survival compared to combination regimens.

The addition of monoclonal antibodies like cetuximab and panitumumab in first-line treatment has not shown a significant improvement in overall survival, suggesting their use should be reconsidered, particularly in patients with KRAS mutations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Chemotherapy of metastatic colorectal cancer. [2013]

In a study of 65 patients with KRAS wild-type metastatic colorectal cancer who were resistant to standard chemotherapy, the combination of panitumumab and irinotecan resulted in an objective response rate of 29.2%, with a median overall survival of 9.7 months.

The treatment was particularly effective in patients without additional mutations, showing a 46.3% response rate, while those with other mutations (NRAS, BRAF, or rare KRAS) did not respond, highlighting the importance of biomarker selection in treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. André, T., Blons, H., Mabro, M., et al.[2023]

Combination therapy using irinotecan or oxaliplatin with infusional 5-FU and folinic acid has increased response rates to about 50% and extended median overall survival to 20 months in patients with metastatic colorectal cancer.

Monoclonal antibodies like bevacizumab and cetuximab have shown to significantly enhance treatment outcomes, with bevacizumab extending survival by over 4 months compared to chemotherapy alone, and cetuximab being effective after progression with irinotecan.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[New therapy options in colorectal carcinoma]. Folprecht, G., Köhne, CH.[2018]

In a phase Ib study involving 6 Japanese patients with metastatic colorectal carcinoma, the combination of ramucirumab and FOLFIRI was found to be well-tolerated, with only one patient experiencing a dose-limiting toxicity.

While all patients had at least one grade 3 or higher adverse event, there were no serious adverse events or deaths, suggesting that this treatment combination is relatively safe for further investigation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. Yoshino, T., Yamazaki, K., Gotoh, M., et al.[2023]

In a real-world study of 362 patients with metastatic colorectal cancer treated with ramucirumab + FOLFIRI, 84.3% experienced adverse events, with common issues including decreased neutrophil count, hypertension, and diarrhea, indicating that while the treatment is effective, it does carry a significant risk of side effects.

The 12-month survival rate for patients on the ramucirumab + FOLFIRI regimen was 59%, with most mortality attributed to disease progression rather than treatment-related complications, suggesting that the regimen is manageable and aligns with previous clinical trial safety profiles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer. Masuishi, T., Nagaoka, S., Jin, L., et al.[2022]

The TRIPLETE study is a phase III trial comparing two chemotherapy regimens (mFOLFOX6 and modified FOLFOXIRI) combined with panitumumab in patients with RAS and BRAF wild-type metastatic colorectal cancer, aiming to determine which regimen provides a better overall response rate.

This study is significant as it seeks to clarify the effectiveness of intensified chemotherapy in combination with anti-EGFR therapy, addressing a gap in knowledge regarding treatment options for this specific patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. Borelli, B., Moretto, R., Lonardi, S., et al.[2022]

In a study of 154 patients with metastatic colorectal carcinoma (mCRC), the combination of panitumumab and FOLFIRI showed a higher objective response rate (ORR) in patients with RAS wild type (WT) tumors (59%) compared to those with RAS mutant (MT) tumors (41%).

The treatment was well tolerated, with no new safety concerns, and patients with RAS WT tumors experienced longer median response durations (13.0 months) and progression-free survival (11.2 months) compared to those with RAS MT tumors (5.8 months and 7.3 months, respectively).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Karthaus, M., Hofheinz, RD., Mineur, L., et al.[2018]

In a meta-analysis of four randomized controlled trials involving 1270 patients with metastatic colorectal cancer, adding cetuximab or panitumumab to oxaliplatin-based chemotherapy did not significantly improve overall survival or progression-free survival for KRAS wild type patients.

The combination therapy did not enhance the overall response rate compared to chemotherapy alone, and while there was a slight increase in toxicities with anti-EGFR drugs, the overall efficacy of the treatment remained unchanged.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. Zhou, SW., Huang, YY., Wei, Y., et al.[2023]

In a study of 66 patients with chemotherapy-refractory metastatic colorectal cancer, the combination of cetuximab with bevacizumab and mFOLFOX6 showed manageable safety, but significant toxicity led to a high discontinuation rate, with 56% of patients stopping treatment before disease progression.

Despite not causing excessive life-threatening toxicity, the addition of cetuximab resulted in a notable number of patients experiencing severe side effects, prompting the conclusion that this combination therapy should not be used together for treating metastatic colorectal cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Ocean, AJ., Polite, B., Christos, P., et al.[2021]

Panitumumab has shown promising antitumor activity in metastatic colorectal cancer, achieving a 10% response rate as a standalone treatment and a 36% response rate when combined with chemotherapy, based on phase II studies.

In a phase III study, panitumumab demonstrated a significant clinical advantage over best supportive care as a third-line monotherapy, and it has a good tolerability profile with no maximum tolerated dose established.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. Martinelli, E., Morgillo, F., Troiani, T., et al.[2021]

A 66-year-old male with metastatic rectal adenocarcinoma developed acute pulmonary fibrosis after 12 cycles of chemotherapy with oxaliplatin and 5-FU/folinic acid, highlighting a rare but serious side effect of this treatment regimen.

Despite the regimen being generally well tolerated, this case emphasizes the need for clinicians to consider pulmonary toxicity early when patients present with unexplained pulmonary infiltrates, as timely recognition may improve patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer. Mundt, P., Mochmann, HC., Ebhardt, H., et al.[2022]

In a phase II trial involving 31 patients with metastatic colorectal cancer, the combination of FOLFOX, bevacizumab, and cetuximab achieved a 55% objective response rate and a median overall survival of 25.7 months, indicating promising efficacy.

The treatment regimen was generally well-tolerated, although significant side effects were observed, including neutropenia and rash; the role of cetuximab in enhancing efficacy remains uncertain and should be further evaluated with K-RAS testing in future studies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer. Spigel, DR., Greco, FA., Waterhouse, D., et al.[2015]

Citations

1. trialfinder.panfoundation.org trialfinder.panfoundation.org/en-US/trial/listing/454176

Sotevtamab (AB-16B5) Combined With FOLFOX as ... This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11049052/

Therapeutic Potential of Clusterin Inhibition in Human Cancer As a therapeutic target, the inhibition of CLU has demonstrated excellent therapeutic effects in various cancers both in vitro and in vivo, prolonging the ...

3. researchgate.net researchgate.net/publication/318804777_Abstract_CT098_Phase_1_first-in-human_study_of_anti-clusterin_antibody_AB-16B5_in_patients_with_advanced_solid_malignancies

Phase 1 first-in-human study of anti-clusterin antibody AB ... Background. Secreted clusterin (sCLU) promotes survival and stimulates epithelial to mesenchymal transition (EMT) in cancer cells, leading to tumor invasion ...

4. adisinsight.springer.com adisinsight.springer.com/drugs/800038164

Alethia Biotherapeutics - Sotevtamab - AdisInsight - Springer Phase II Colorectal cancer; Non-small cell lung cancer; No development reported Solid tumours. Most Recent Events. 31 May 2024 Efficacy and adverse events data ...

5. synapse.patsnap.com synapse.patsnap.com/drug/9f151dc74ed54a278da990a4b591b735

Sotevtamab - Drug Targets, Indications, Patents A proof-of-concept phase II trial to evaluate the EMT inhibitor Sotevtamab combined with FOLFOX administered as neoadjuvant treatment prior to resection of ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC4127629/

Safety Analysis of FOLFOX4 Treatment in Colorectal ... To evaluate the safety data of FOLFOX regimen in Japanese patients and to comply with a conditional approval commitment, a study termed “Post Marketing ...

7. brieflands.com brieflands.com/articles/ijcm-9429

A Comparative Study of Treatment Toxicities Between ... FOLFOX has effectively increased the progression free survival (PFS) in colorectal cancer patients (2). There are two common types of FOLFOX regimens: FOLOFOX 4 ...

8. sciencedirect.com sciencedirect.com/science/article/abs/pii/S1533002811001253

Safety Analysis of FOLFOX4 Treatment in Colorectal ... A total of 3359 patients with colorectal cancer treated with the FOLFOX4 regimen were included in the analyses: 1515 from 2 Asian studies (Japanese Post ...

9. nejm.org nejm.org/doi/full/10.1056/NEJMoa032709

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant ... Although more frequent among patients receiving FL plus oxaliplatin than among those treated with FL alone, grade 3 or 4 neutropenia led to fever or infection ...

10. bmccancer.biomedcentral.com bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12662-3

Safety of first-line systemic therapy in patients with metastatic ... FOLFOX + panitumumab. These results indicate a lower risk of mucositis or stomatitis for CAPOX and FOLFOX regimens, as shown in Supplementary ...